Beam Therapeutics
BEAM
214 hedge funds and large institutions have $1.82B invested in Beam Therapeutics in 2024 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 41 closing their positions.
133% more call options, than puts
Call options by funds: $16.6M | Put options by funds: $7.11M
18% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 62
8.14% more ownership
Funds ownership: 86.14% → 94.28% (+8.1%)
3% less funds holding
Funds holding: 221 → 214 (-7)
12% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 41
22% less capital invested
Capital invested by funds: $2.32B → $1.82B (-$504M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
+$134M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$83.5M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$36.4M |
| 4 |
BlackRock
New York
|
+$22.8M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$19.7M |
Top Sellers
BEAM Hedge Fund Activity: Q2 2024 in Review
214 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2024, worth a combined $1.82B — down 22% from $2.32B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of BEAM and 36 opened new positions — a net loss of 5 holders — while 62 trimmed existing stakes and 73 added.
The largest buyer was Arch Venture Management, opening a new position worth an estimated $134M. The largest seller was Morgan Stanley, cutting an estimated $81.5M.
- 214 institutional investors held Beam Therapeutics (BEAM) as of Q2 2024, down from 221 in Q1 2024.
- Funds reported $1.82B of Beam Therapeutics stock for Q2 2024, down 22% quarter-over-quarter.
- 36 funds opened new Beam Therapeutics positions in Q2 2024 and 41 closed out, a net change of -5 holders.
- The largest Beam Therapeutics buyer in Q2 2024 was Arch Venture Management, an estimated $134M added.
- The largest Beam Therapeutics seller in Q2 2024 was Morgan Stanley, an estimated $81.5M sold.
Based on aggregated 13F filings for Q2 2024.